As with GBM patients, patients with lower grade tumors but PTPμ high levels had longer overall survival than those with PTPμ low levels, although this difference was only significant after adjusting for sex, age group, and IDH1 mutation status (Figure 6b). This evidence concerns the gene IDH1 and glioblastoma.